Amgen
As of the edition of 20 October 2026, Amgen runs 158 drugs, 44 of them marketed; it is on route A at 41 targets and on route B at 19 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Amgen was merged.
The records place 14 company names in this family.
- Onyx Pharmaceuticals Inc A Wholly Owned Sub Of Amgen Inc: acquired in 2013; successor AMGEN INC
- Viela Bio: acquired in 2021; successor Horizon Therapeutics Usa Inc
- Five Prime Therapeutics, Inc.: acquired in 2021; successor AMGEN INC
- Chemocentryx Inc: acquired in 2022; successor AMGEN INC
- AMGEN INC: merged
Drugs by status
| Status | Count |
|---|---|
| Marketed | 44 |
| Active | 25 |
| Went quiet | 26 |
| Stopped | 49 |
| Status not established | 14 |
| Total | 158 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Bevacizumab | Ends 2027 (orphan exclusivity) | 2 |
| Prednisone | none listed | 1 |
| Filgrastim | Ended 2022 (orphan exclusivity) | 3 |
| Trastuzumab | Ended 2017 (orphan exclusivity) | 0 |
| Adalimumab | Ends 2028 (orphan exclusivity) | 4 |
| Aflibercept | Ends 2030 (orphan exclusivity) | 4 |
| Infliximab | Ended 2018 (orphan exclusivity) | 3 |
| Etanercept | Ended 2010 (computed from the first US licence) | 2 |
| Pegfilgrastim | Ended 2022 (orphan exclusivity) | 3 |
| Epoetin alfa | Ended 2001 (computed from the first US licence) | 1 |
| Diclofenac | none listed | 7 |
| Carfilzomib | Ends 2028 (exclusivity) | 2 |
| Panitumumab | Ended 2018 (computed from the first US licence) | 1 |
| Thiotepa | none listed | 0 |
| Denosumab | Ended 2022 (computed from the first US licence) | 1 |
| Blinatumomab | Ends 2031 (orphan exclusivity) | 0 |
| Ustekinumab | Ended 2021 (computed from the first US licence) | 1 |
| Anakinra | Ends 2027 (orphan exclusivity) | 0 |
| Apremilast | Ends 2028 (patent) | 4 |
| Darbepoetin alfa | Ended 2013 (computed from the first US licence) | 1 |
| Evolocumab | Ends 2028 (orphan exclusivity) | 2 |
| Interferon gamma-1b | Ended 2011 (computed from the first US licence) | 0 |
| Romiplostim | Ends 2028 (orphan exclusivity) | 2 |
| Sotorasib | Ends 2040 (patent) | 1 |
| Ivabradine | Ends 2026 (patent) | 3 |
A route B row is one company at one target. 19 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 41 targets, route B at 19 targets.
All 60 rows on route A or B
In the product60 company-target rows on route A or B; 57 are not shown here, and no score is.
See all 60 targets where Amgen needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 208 trials led
- Immune system: 177 trials led
- Skin and connective tissue: 126 trials led